SynthesisEuropean radiology2018
Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis.
Synthesis in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Node-RADS: a systematic review and meta-analysis of diagnostic performance, category-wise malignancy rates, and inter-observer reliability.European radiology · 2025Pooled it
- Improving the malignancy prediction of breast cancer based on the integration of radiomics features from dual-view mammography and clinical parameters.Clinical and experimental medicine · 2023Trial
- Magnetic Resonance Imaging Features in Diagnosis of Breast Cancer and Evaluation of Effect of Epidermal Growth Factor Receptor-Targeted Therapy.BioMed research international · 2022Trial
- Cost-Effectiveness Analysis of Axillary Management Options at the Time of Contralateral Prophylactic Mastectomy.Annals of surgical oncology · 2026Article
- Uptake Patterns of [Cancers · 2026Article
- Integrated [European journal of nuclear medicine and molecular imaging · 2026Article
- "Cloud sign" in automated breast volume scanning coronal images for the differential diagnosis of benign and malignant breast lesions.Quantitative imaging in medicine and surgery · 2025Article
- Diagnostic accuracy of a machine learning model using radiomics features from breast synthetic MRI.BMC medical imaging · 2025Article
- Study on ABUS Applicability for Rural Women With Low Health Resources in China-Large-Scale Population, Non-Opportunistic Screening.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025Article
- Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals.BMC biology · 2025Article
- Stratifying Breast Lesion Risk Using BI-RADS: A Correlative Study of Imaging and Histopathology.Medicina (Kaunas, Lithuania) · 2025Article
- A preliminary study on the diagnostic value of contrast-enhanced ultrasound and micro-flow imaging for detecting blood flow signals in breast cancer patients.Gland surgery · 2024Article
- Third-look contrast-enhanced ultrasonography plus needle biopsy for differential diagnosis of magnetic resonance imaging-only detected breast lesions.Journal of medical ultrasonics (2001) · 2024Review
- Follow-up results of BI-RADS 3 lesions on magnetic resonance imaging: a retrospective studyDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- The role of gadolinium-based contrast agents in magnetic resonance imaging structured reporting and data systems (RADS).Magma (New York, N.Y.) · 2024Review
- Review
- The value of MRI for downgrading of breast suspicious lesions detected on ultrasound.BMC medical imaging · 2023Article
- Does MRI have added value in ultrasound-detected BIRADS-3 breast masses in candidates for assisted reproductive therapy?European journal of radiology open · 2023Article
- [Breast Imaging Reporting and Data System (BI-RADS): Advantages and Limitations].Journal of the Korean Society of Radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate prevalence, malignancy rates, imaging features, and follow-up intervals for probably benign (BI-RADS 3) lesions on breast magnetic resonance imaging (MRI).
methodsA systematic database-review of articles published through 22/06/2016 was performed. Eligible studies reported BI-RADS 3 lesions on breast MRI. Two independent reviewers performed a literature review and data extraction. Data collection included study characteristics, number/type of BI-RADS 3 lesions, final diagnosis (histopathology and/or follow-up). Sources of bias (QUADAS-2) were assessed. Meta-analysis included data-pooling, heterogeneity testing, and meta-regression.
resultsFifteen studies were included. Prevalence was reported in 11 studies (range: 1.2-24.3%). Malignancy rates ranged between 0.5-10.1% (pooled 61/2814, 1.6%, 95%-CI:0.9-2.3% (random-effects-model), I
conclusionWhile prevalence of MRI BI-RADS 3 lesions was strongly heterogeneous, pooled malignancy rates met BI-RADS benchmarks (<2%). Malignancy rates varied, exceeding 2% in non-mass lesions. Twenty-four-month surveillance is required to detect all malignant lesions. KEY POINTS: • Probably benign (BI-RADS 3) lesions showed a pooled malignancy-rate of 1.6% (95%-CI:0.9-2.3%). • Malignancy rates differ and are highest in non-mass lesions (2.3%, 95%-CI:0.8-3.9%). • The prevalence of BI-RADS 3 lesions on breast MRI ranged from 1.2-24.3%. • Malignant lesions were diagnosed at follow-up time points up to 24 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.